In Re Brand Name Prescription Drugs Antitrust Litigation PDF Download

Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download In Re Brand Name Prescription Drugs Antitrust Litigation PDF full book. Access full book title In Re Brand Name Prescription Drugs Antitrust Litigation.

In Re: Tamoxifen-citrate Antitrust Litigation

In Re: Tamoxifen-citrate Antitrust Litigation
Author:
Publisher:
Total Pages: 42
Release: 2005
Genre: Antitrust law
ISBN:

Download In Re: Tamoxifen-citrate Antitrust Litigation Book in PDF, ePub and Kindle

The plaintiffs in In re: Taxmoxifen Citrate Antitrust Litigation (who include pharmaceutical consumers, third party payors, and a health care advocacy group) filed a Petition for Writ of Certiorari asking the Supreme Court to review the Second Circuit's decision affirming the dismissal of this antitrust case. The plaintiffs alleged antitrust violations based on a $21 million payment from AstraZeneca (the tamoxifen NDA holder) to Barr Labs (the ANDA filer) in exchange for Barr's promise to withdraw its Paragraph IV certification and abandon its challenge of the tamoxifen patent.


In Re: Ciprofloxacin Hydrochloride Antitrust Litigation

In Re: Ciprofloxacin Hydrochloride Antitrust Litigation
Author:
Publisher:
Total Pages: 40
Release: 2008
Genre: Antitrust law
ISBN:

Download In Re: Ciprofloxacin Hydrochloride Antitrust Litigation Book in PDF, ePub and Kindle

The plaintiffs in In re: Ciprofloxacin hydrochloride (Cipro) Antitrust Litigation (consumers and advocacy groups), sued the the brand name antibiotic's manufacturer Bayer, and prospective manufacturers of cheaper generic version, claiming that the exclusion agreement under which proposed manufacturers agreed to defer entry into market until expiration of patent held by Bayer, in return for payments to be received from Bayer, was in violation of antitrust laws. This amicus brief supports the plaintiffs, arguing in part that the case should have been decided in federal circuit court and that exclusion payments are generally anticompetitive.


Private Antitrust Actions

Private Antitrust Actions
Author: C. Douglas Floyd
Publisher: Aspen Publishers
Total Pages: 296
Release: 1996
Genre: Actions and defenses
ISBN:

Download Private Antitrust Actions Book in PDF, ePub and Kindle

Here For The first time is a comprehensive one-volume analysis that helps you to evaluate and successfully bring or defend a private antitrust suit. With Private Antitrust Actions you'll know exactly what it takes to determine if a party has standing to bring a civil antitrust suit, take advantage of (or overcome) available exemptions and immunities, and counsel any business on effective antitrust strategy. With detailed information on how the amount of the award is calculated, you'll be able to evaluate each case for potential recovery (or costs) and attorney's fees. And you'll also see how the federal courts are now interpreting and applying standards governing such matters as: Antitrust injury and standing Federal preemption Insurance exemption for HMOs and managed care plan Labor exemption and professional sports State action immunity Statute of limitations and fraudulent concealment Class certification and settlement Summary judgment and judgment as a matter of law Expert testimony in establishing damages ...plus in-depth exploration of areas where conflicting authority and unresolved questions persist.


In Re: Tamoxifen-citrate Antitrust Litigation

In Re: Tamoxifen-citrate Antitrust Litigation
Author:
Publisher:
Total Pages: 44
Release: 2005
Genre: Antitrust law
ISBN:

Download In Re: Tamoxifen-citrate Antitrust Litigation Book in PDF, ePub and Kindle

The case concerns a decision by a divided panel of the Appeals Court upholding the dismissal of an antitrust challenge to a patent litigation settlement between AstraZeneca, the manufacturer of tamoxifen citrate, the most widely prescribed drug for breast cancer treatment, and Barr Labs., a U.S. Food and Drug Administration applicant for a generic counterpart.